A landmark clinical trial of semaglutide, published in 2021, found that participants experienced an average of 15% weight loss over the course of 68 weeks while those on placebo lost 2%
Long-Term Weight Loss & Maintenance with Semaglutide in Obesity (2022 Review of STEP Trials) consolidates findings across multiple STEP trials (1, 3, 4, 8), showing 14.917.4% mean weight loss over 68 weeks, improved cardiometabolic markers, and better quality-of-life outcomes
True Value Score: A Pricing Medication Costs Insurance Cancellations, Refunds, and Commitment Terms Shed requires a minimum two-month commitment, and cancellations must be made at least 72 hours before the next billing cycle to avoid charges
Data Charting Relevant information from each included study was extracted using a data charting form that captured the following fields: author(s), year of publication, country of origin, whether the combination was an add-on or simultaneously used, study population characteristics relevant to the outcomes, and sample size, study design, intervention or exposition type and details of these, comparator, outcomes and their specifics, adverse effects reports, and key findings related to the scoping review questions
Silva, A
